**Methods: estimation of patient population**

It was assumed that, on a national level, each year a total of 610 patients with refractory left-ventricular CS would be eligible for either Impella 5.0 or VA-ECMO.

In the absence of studies quantifying the exact number of CS patients in France, data from the French Programme de médicalisation du système d’informations-Médecine Chirurgie Obstétrique (PMSI-MCO) 2015–2016 were used to estimate the size of the target population eligible for Impella 5.0 in for the two indications included in the analysis.[[1]](#endnote-1) Specifically, the PMSI-MCO 2015–2016 was used to identify all patients aged 18–65 years, with no contraindications diagnosed with CS (ICD-10 code: R570) after having undergoing cardiac surgery (n=416) as well as patients aged 18–65 years, with no contraindications who developed CS prior to LVAD implantation or cardiac transplant (n=416)(total population rounded to N=610 patients).

**References**

1. Programme de médicalisation du système d’informations-Médecine Chirurgie Obstétrique. Available at: <https://www.scansante.fr/opendata/pmsi-mco> [Last accessed March 18, 2020] [↑](#endnote-ref-1)